DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Alendronate (Alendronate Sodium) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Treatment of Osteoporosis in Postmenopausal Women

Alendronate Sodium Tablet is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women,  Alendronate Sodium Tablet increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [See Clinical Studies].

Prevention of Osteoporosis in Postmenopausal Women

Alendronate Sodium Tablet is indicated for the prevention of postmenopausal osteoporosis [see Clinical Studies].

Treatment to Increase Bone Mass in Men with Osteoporosis

Alendronate Sodium Tablet is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies].

Treatment of Glucocorticoid-Induced Osteoporosis

Alendronate Sodium Tablet is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see Clinical studies].

Treatment of Paget's Disease of Bone

Alendronate Sodium Tablet is indicated for the treatment of Paget’s disease of bone in men and women. Treatment is indicated in patients with Paget’s disease of bone who have alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease. [see Clinical Studies].

Important Limitations of Use

The optimal duration of use has not been determined. The safety and effectiveness of Alendronate Sodium for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.

DOSAGE AND ADMINISTRATION

Treatment of Osteoporosis in Postmenopausal Women

The recommended dosage is:

  • One 70 mg tablet once weekly  OR
  • One 10 mg tablet once daily

Prevention of Osteoporosis in Postmenopausal Women

The recommended dosage is:

  • One 35 mg tablet once weekly  OR
  • One 5 mg tablet once daily

Treatment to Increase Bone Mass in Men with Osteoporosis

The recommended dosage is:

  • One 70 mg tablet once weekly  OR
  • One 10 mg tablet once daily

Treatment of Glucocorticoid-Induced Osteoporosis

The recommended dosage is one 5 mg tablet once daily, except for postmenopausal women not receiving estrogen, for whom the recommended dosage is one 10 mg tablet once daily.

Treatment of Paget's Disease of Bone

The recommended treatment regimen is 40 mg once a day for six months.

Re-treatment of Paget's Disease

Re-treatment with Alendronate Sodium Tablet may be considered, following a six-month post-treatment evaluation period in patients who have relapsed, based on increases in serum alkaline phosphatase, which should be measured periodically. Re-treatment may also be considered in those who failed to normalize their serum alkaline phosphatase.

Important Administration Instructions

Instruct patients to do the following:

  • Take Alendronate Sodium Tablet at least one-half hour before the first food, beverage, or medication of the day with plain water only [see Patient Counseling Information]. Other beverages (including mineral water), food, and some medications are likely to reduce the absorption of Alendronate Sodium Tablet [see Drug Interactions]. Waiting less than 30 minutes, or taking Alendronate Sodium Tablet with food, beverages (other than plain water) or other medications will lessen the effect of Alendronate Sodium by decreasing its absorption into the body.
  • Take Alendronate Sodium Tablet upon arising for the day. To facilitate delivery to the stomach and thus reduce the potential for esophageal irritation, an Alendronate Sodium Tablet should be swallowed with a full glass of water (6-8 ounces). Patients should not lie down for at least 30 minutes and until after their first food of the day. Alendronate Sodium Tablet should not be taken at bedtime or before arising for the day. Failure to follow these instructions may increase the risk of esophageal adverse experiences [see Warnings and Precautions and Patient Counseling Information].

Recommendations for Calcium and Vitamin D Supplementation

Instruct patients to take supplemental calcium if dietary intake is inadequate[see Warnings and Precautions]. Patients at increased risk for vitamin D insufficiency (e.g., over the age of 70 years, nursing home-bound, or chronically ill) may need vitamin D supplementation. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplementation and measurement of 25-hydroxyvitamin D should be considered.

Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D.

Administration Instructions for Missed Doses

If a Once-weekly dose of Alendronate Sodium Tablet is missed, instruct patients to take one dose on the morning after they remember. They should not take two doses on the same day but should return to taking one dose once a week, as originally scheduled  on their chosen day.

DOSAGE FORMS AND STRENGTHS

Alendronate Sodium Tablets USP, 35 mg
White to off white, oval, uncoated tablets, debossed with 'J' on one side and '242' on the other side.

Alendronate Sodium Tablets USP, 70 mg
White to off white, oval, uncoated tablets, debossed with 'J' on one side and '244' on the other side.

HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED

Alendronate Sodium Tablets USP, 35 mg

White to off white, oval, uncoated tablets, debossed with ‘J’ on one side and ‘242’ on the other side.

Unit-of-use Blister package of 4 tablets, NDC 59746-242-02

Alendronate Sodium Tablets USP, 70 mg

White to off white, oval, uncoated tablets, debossed with ‘J’ on one side and ‘244’ on the other side.

Unit-of-use Blister package of 4 tablets, NDC 59746-244-02

Storage:

Store in a well closed container at 20 - 25°C (68 - 77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].

Keep this and all medicines out of the reach of children.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015